Fragile X syndrome — branching viva

Opening framework

My framework has four layers. First, the indication — any child with unexplained intellectual disability or developmental delay, especially a boy, and any child with autism and intellectual involvement, warrants fragile X testing. Second, the investigation — a two-part molecular assay of FMR1 PCR plus methylation analysis, because karyotype and microarray miss the repeat expansion. Third, the mechanism — a CGG-repeat expansion that methylates and silences FMR1, abolishing FMRP, the synaptic translational brake. Fourth, the family — cascade testing of the mother, siblings, and at-risk relatives, with premutation surveillance. [1]

Why the normal microarray does not exclude fragile X

Chromosomal microarray detects copy-number variants across the genome and is the first-tier test for unexplained intellectual disability, but it does not detect the FMR1 CGG-repeat expansion. So a normal microarray has excluded large deletions and duplications, not fragile X. The two-part molecular test I order is FMR1 PCR — which measures the repeat number and detects premutation alleles — plus methylation-sensitive PCR or Southern blot, which sizes the full mutation and confirms methylation-driven silencing. Ordering only one fails: PCR may not size a very large full mutation, and methylation alone may miss a premutation. [1] [5]

Classifying the allele and the pathophysiology

The four allele classes are normal (5 to 44 repeats), intermediate (45 to 54), premutation (55 to 200), and full mutation (over 200). The boundary at about 200 repeats is where the gene tips from expressed to silenced: beyond it, the adjacent CpG island hypermethylates, FMR1 is transcriptionally silenced, and FMRP is absent. FMRP is an RNA-binding protein that represses target-mRNA translation at the synapse; without it, group 1 mGluR-linked long-term depression runs unchecked, dendritic spines stay immature, and the child develops intellectual disability, autism features, seizures, and sensory hypersensitivity. [3] [5]

The management framework

Management is a five-step framework: confirm the molecular diagnosis, assemble a multidisciplinary baseline assessment, build developmental and educational support, treat comorbidity with behavioural and pharmacological tools, and run cascade testing with genetic counselling. The backbone is developmental support — early intervention, individualised education plans, speech and language therapy, occupational therapy, and augmentative communication. Pharmacological treatment is strictly comorbidity-led: stimulants or alpha-2 agonists for ADHD, SSRIs for anxiety, anticonvulsants for seizures. No disease-modifying drug has succeeded in pivotal trials, despite the strong mGluR-theory rationale, so I counsel families honestly and protect them from unsupported treatments. [1] [6]

Branch: the mother with a 110-repeat premutation

For the mother carrying a premutation of 110 CGG repeats, I apply the maternal-expansion rule. A premutation of about 90 repeats or more carries a very high risk of expanding to a full mutation in her offspring, so each pregnancy carries a 50 percent chance of transmission and a high conditional risk of the transmitted allele being a full mutation. She is counselled on prenatal or preimplantation genetic diagnosis for future pregnancies. She is also at risk of two premutation-associated conditions herself: fragile X-associated tremor/ataxia syndrome, an adult-onset neurodegenerative disorder with intention tremor, ataxia, and cognitive decline, and fragile X-associated primary ovarian insufficiency, with subfertility and early menopause. I arrange baseline neurological and ovarian-hormone surveillance. [9]

Closing: cascade testing and the trap to avoid

The closing point is the cascade-testing obligation and the classic trap. Once an index case is confirmed, the mother, siblings, and all at-risk maternal relatives should be offered testing, because carriers and affected relatives are routinely missed. The trap is to ration testing on the argument that the result would not change management — it changes educational support, reproductive counselling, and family diagnosis. The plan is shared: the genetics service owns the counselling and cascade testing, the general practitioner owns coordination and preventive care, and a written, reconciled record travels with the child through every transition. [1] [9]